EWErin N. Wakeling

Erin N. Wakeling

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Erin N. Wakeling has a total of 19 co-authors. Here are the top co-authors by number of shared publications:

  • Béatrice Joussemet

    INSERM UMR1089, Institut de Recherche Thérapeutique 1, Université de Nantes, 44007 Nantes Cedex 01, France

    2 shared publications
  • Martine Barkats

    INSERM UMR974, Institut de Myologie, Faculté de Médecine, 75013 Paris, France

    2 shared publications
  • Philippe Moullier

    INSERM UMR1089, Institut de Recherche Thérapeutique 1, Université de Nantes, 44007 Nantes Cedex 01, France

    2 shared publications
  • Delphine Briot-Nivard

    INSERM UMR1089, Institut de Recherche Thérapeutique 1, Université de Nantes, 44007 Nantes Cedex 01, France

    1 shared publication
  • Dominique Fanuel

    National Veterinary School of Nantes, ONIRIS, Nantes, France

    1 shared publication
  • John C. Fyfe

    From the Genetics Program, Michigan State University, East Lansing, MI 48824 (Wakeling and Fyfe); and the Department of Microbiology & Molecular Genetics, College of Veterinary Medicine, Michigan State University, East Lansing, MI 48824 (Fyfe)

    1 shared publication

Latest Publications

  • scAAV9 Intracisternal Delivery Results in Efficient Gene Transfer to the Central Nervous System of a Feline Model of Motor Neuron Disease

    by Thomas Bucher, Marie-Anne Colle, Erin Wakeling, Laurence Dubreil, John Fyfe, Delphine Briot-Nivard, Maud Maquigneau, Sylvie Raoul, Yan Cherel, Stéphanie Astord, et al.

    On the basis of previous studies suggesting that vascular endothelial growth factor (VEGF) could protect motor neurons from degeneration, adeno-associated virus vectors (serotypes 1 and 9) encoding VEGF (AAV.vegf) were administered in a limb-expression 1 (LIX1)-deficient cat—a large animal model of lower motor neuron disease—using three different delivery routes to the central nervous system. AAV.vegf vectors were injected into the motor cortex via intracerebral administration, into the cisterna magna, or intravenously in young adult cats. Intracerebral injections resulted in detectable transgene DNA and transcripts throughout the spinal cord, confirming anterograde transport of AAV via the corticospinal pathway. However, such strategy led to low levels of VEGF expression in the spinal cord. Similar AAV doses injected intravenously resulted also in poor spinal cord transduction. In contrast, intracisternal delivery of AAV exhibited long-term transduction and high levels of VEGF expression in the entire spinal cord, yet with no detectable therapeutic clinical benefit in LIX1-deficient animals. Altogether, we demonstrate (i) that intracisternal delivery is an effective AAV delivery route resulting in high transduction of the entire spinal cord, associated with little to no off-target gene expression, and (ii) that in a LIX1-deficient cat model, however, VEGF expressed at high levels in the spinal cord has no beneficial impact on the disease course. Bucher and colleagues demonstrate that intracisternal delivery of self-complementary AAV9 (scAAV9)-encoding VEGF results in highly robust levels of VEGF protein in the spinal cord of cats. Yet, this approach has no beneficial impact on the disease course of a feline model of lower motor neuron disease.


  • Failure of lower motor neuron radial outgrowth precedes retrograde degeneration in a feline model of spinal muscular atrophy

    by Erin N. Wakeling, Béatrice Joussemet, Patrick Costiou, Dominique Fanuel, Philippe Moullier, Martine Barkats, John C. Fyfe


  • Open Access

    Lix1 Knockout Mouse Does Not Exhibit Spinal Muscular Atrophy Phenotype

    by Erin N. Wakeling, John C. Fyfe

    Feline spinal muscular atrophy (SMA) is an autosomal recessive juvenile onset lower motor neuron disease caused by an ∼140 kb deletion that disrupts expression of 2 genes, limb expression 1 ( LIX1 ) and leucyl/cystinyl aminopeptidase ( LNPEP ). A previously generated Lnpep knockout (KO) mouse did not demonstrate a neuromuscular phenotype. Little is known about LIX1 , except that it is evolutionarily conserved and highly expressed in spinal cord motor neurons. To determine whether loss of LIX1 alone is responsible for the feline SMA phenotype, a Lix1 intron 1 gene trap KO mouse line was obtained from Lexicon Genetics, Inc. Mating of F 1 heterozygotes produced offspring in the expected Mendelian ratios. KO and normal littermates were studied through 2 years of age by hanging latency, rotarod, inked footprint analysis, and histological methods. Disruption of Lix1 expression did not affect survival nor result in any neuromuscular phenotype. Reverse transcriptase–PCR amplification of spinal cord RNA identified a Lix1 alternative transcript beginning in intron 4 and containing exons 5 and 6. The alternative transcript appeared to be rodent specific, and its expression was not disrupted in Lix1 KO mice. Expression of the alternative transcript may have compensated for the loss of Lix1 in the KO mice and thus protected against motor neuron degeneration.